

29 August 2025

CARETEQ'S FY25 PRELIMINARY FULL YEAR RESULTS

Revenue up 5.4% and Group EBITDA up 171% from Continuing Operations

Careteq Limited (ASX: CTQ) ("Careteq" or "the Company"), a clinical healthtech company specialising in innovative medication management and clinical governance solutions, is pleased to release its unaudited preliminary full year results for the period ended 30 June 2025 ("FY25").

Highlights

- Strategic decisions undertaken at the beginning of FY25 have delivered a full year group EBITDA¹ profit from continuing operations of \$0.3 million vs. a loss of \$1.4 million in the prior corresponding period ("pcp")
- Group revenues for continuing operations up 5.4% over pcp to \$7.6 million
- Underlying group EBITDA from continuing operations², which excludes one-off expenditure, up 171% over pcp to \$0.5 million
- Group NPAT (Net Profit after Tax) from continuing operations of \$0.1 million, an 110% improvement over last year loss of (\$1.8 million)
- Embedded Health Solutions (EHS) underlying EBITDA³ up 13% over pcp to \$1.7 million
- Continued revenue growth and positive EBITDA/NPAT expected in FY26 from continuing operations

Executive Chairman, Mark Simari, said:

"FY25 marks an important turning point for Careteq. We simplified the business, focused on our core of medication management and clinical governance, and delivered a return to profitability alongside positive EBITDA from continuing operations. With EHS now fully owned and integration progressing, we are better positioned to scale our platforms moving forward across aged care, home care and disability."

¹Group EBITDA from continuing operations of \$0.3 million was calculated as Loss before tax of \$0.3 million add back Finance charges \$0.2 million and add back Depreciation & amortization \$0.4 million.

²Underlying Group EBITDA from continuing operations of \$0.5 million was calculated as Group EBITDA from continuing operations of \$0.3 million adjusted for once-off costs accounting, audit and legal costs associated with the closure of the US operations and the ATO dispute of \$0.2 million.

³The EHS underlying EBITDA for FY25 of \$1.7 million was calculated as Profit before tax of \$1.3 million add back Finance charges \$0.1 million and add back Depreciation & amortization \$0.3 million. This represents the EHS underlying EBITDA for FY25 on a standalone basis.

Strategic shift delivered positive results

During the period, the Company divested its loss-making Sofihub business. It subsequently acquired the remaining 45% of its profitable Embedded Health Solutions (EHS) business unit for \$2.4 million. The result is a streamlined business with a clear focus on medication management and clinical governance.

These strategic transactions are now bearing fruit, with the Company delivering a maiden EBITDA positive half from continuing operations.

Whilst some synergies have been extracted through EHS integration, further synergies are expected upon the completion the 1-system initiative whereby EHS, Mederev and HMR Referrals platforms are consolidated. The end result will be an integrated solution across residential aged care, home care, and disability sectors while decommissioning high-cost legacy platforms.

Embedded Health Solutions delivers 5% revenue growth and underlying EBITDA up 13%

EHS underlying EBITDA increased to \$1.7 million for the full year with continued growth expected for FY26.

EHS continues to optimise operational efficiency, with benefits being realised through group synergies. This has already boosted financial performance whilst enabling high-quality care to residents in the aged care sector.

HMR Referrals

Careteq has established partnerships with several large national GP networks to improve medication safety for Australians with chronic conditions. The reach of these partnerships is estimated to be c.100,000 members, c.2,000 GPs and potentially c.500,000 plus referrals onto the HMR Referrals marketplace platform. Management is looking forward to working with these partnerships to drive further growth for the group through FY26.

ATO Update & Audit Status

In late May 2025 the ATO issued the Company with amended assessments relating to historical R&D Tax Incentive claims (FY21–FY23). The ATO's position includes repayment of \$2.6m, penalties of \$0.65m and interest of \$0.34m. Careteq has lodged formal objections across all three elements and continues to work closely with its legal advisors, Minter Ellison to resolve the matter.

Outlook

The Company will continue to balance managing its business operations to drive continued profitability across its Embedded Health Solutions and HMR Referrals platforms whilst working with its legal advisors and the ATO to resolve the R&D Incentive dispute.

Careteq expects full year operational revenue and EBITDA growth from continued operations in FY26.

This ASX announcement has been authorised by the Board of Careteq Limited (ASX: CTQ)

For further information, please contact:**Careteq Limited (ASX: CTQ)**

Mark Simari
Executive Chairman
P: +61 3 8866 5594
E: info@careteq.com.au

About Careteq Limited (ASX: CTQ)

Careteq Limited (ASX: CTQ) is an Australian healthtech company focused on innovative medication management solutions. The Company is dedicated to improving healthcare outcomes through its fully owned Embedded Health Solutions (EHS) and HMR Referrals platforms. EHS provides comprehensive aged care medication management solutions through Residential Medication Management Reviews (RMMRs), while HMR Referrals streamlines Home Medicines Reviews (HMRs).

To learn more, please visit: www.careteq.com.au/

Forward-looking statements

This announcement contains or may contain forward-looking statements that are based on Careteq's beliefs, assumptions, and expectations and on information currently available to Careteq. All statements that address operating performance, events or developments that Careteq or its directors expect or anticipate will occur in the future are forward-looking statements, including, without limitation, statements as to the expectations of Careteq or the market it operates in.

Careteq believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Careteq does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

No assurance or guarantee is, or should be taken to be, given in relation to, and no reliance should be placed on, the future business performance or results of Careteq or the likelihood that the current assumptions, estimates or outcomes will be achieved. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

For more information

Follow us on [LinkedIn](#)

To learn more about Careteq please click here: <https://www.careteq.com.au/investors-centre/>